JPMorgan Chase & Co’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.59K | Sell |
4,606
-29,813
| -87% | -$42.6K | ﹤0.01% | 5505 |
|
|
2025
Q1 | $55.1K | Buy |
34,419
+1,010
| +3% | +$1.62K | ﹤0.01% | 5004 |
|
|
2024
Q4 | $120K | Buy |
33,409
+7,630
| +30% | +$27.5K | ﹤0.01% | 4711 |
|
|
2024
Q3 | $147K | Buy |
25,779
+786
| +3% | +$4.48K | ﹤0.01% | 4578 |
|
|
2024
Q2 | $115K | Buy |
24,993
+24,987
| +416,450% | +$115K | ﹤0.01% | 4530 |
|
|
2024
Q1 | $49 | Sell |
6
-6,887
| -100% | -$56.2K | ﹤0.01% | 6029 |
|
|
2023
Q4 | $38.9K | Sell |
6,893
-2,242
| -25% | -$12.7K | ﹤0.01% | 5078 |
|
|
2023
Q3 | $17K | Buy |
9,135
+7,632
| +508% | +$14.2K | ﹤0.01% | 5184 |
|
|
2023
Q2 | $4.13K | Sell |
1,503
-32,360
| -96% | -$89K | ﹤0.01% | 5306 |
|
|
2023
Q1 | $107K | Sell |
33,863
-66,619
| -66% | -$211K | ﹤0.01% | 4620 |
|
|
2022
Q4 | $592K | Buy |
100,482
+74,117
| +281% | +$437K | ﹤0.01% | 3665 |
|
|
2022
Q3 | $231K | Buy |
26,365
+1,583
| +6% | +$13.9K | ﹤0.01% | 4107 |
|
|
2022
Q2 | $187K | Sell |
24,782
-44,638
| -64% | -$337K | ﹤0.01% | 4351 |
|
|
2022
Q1 | $1.68M | Buy |
69,420
+40,698
| +142% | +$987K | ﹤0.01% | 3294 |
|
|
2021
Q4 | $925K | Sell |
28,722
-26,107
| -48% | -$841K | ﹤0.01% | 3740 |
|
|
2021
Q3 | $2.45M | Buy |
54,829
+38,293
| +232% | +$1.71M | ﹤0.01% | 3043 |
|
|
2021
Q2 | $625K | Buy |
16,536
+10,325
| +166% | +$390K | ﹤0.01% | 3873 |
|
|
2021
Q1 | $230K | Buy |
6,211
+1,424
| +30% | +$52.7K | ﹤0.01% | 4397 |
|
|
2020
Q4 | $159K | Buy |
+4,787
| New | +$159K | ﹤0.01% | 4207 |
|